MiniMed Group (NASDAQ:MMED) Price Target Raised to $28.00

MiniMed Group (NASDAQ:MMED) had its price objective hoisted by BTIG Research from $25.00 to $28.00 in a report issued on Tuesday morning, MarketBeat Ratings reports. BTIG Research currently has a buy rating on the stock.

Other research analysts also recently issued reports about the company. Bank of America dropped their price target on MiniMed Group from $27.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, May 18th. UBS Group assumed coverage on shares of MiniMed Group in a report on Tuesday, July 28th. They issued a “buy” rating and a $25.00 target price on the stock. Wells Fargo & Company reduced their price target on shares of MiniMed Group from $26.00 to $22.00 and set an “overweight” rating on the stock in a report on Thursday, June 4th. Piper Sandler reiterated a “neutral” rating and issued a $16.00 price target on shares of MiniMed Group in a research note on Thursday, June 4th. Finally, Weiss Ratings raised shares of MiniMed Group from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 20th. Thirteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $23.77.

MiniMed Group Stock Up 0.3%

Shares of MiniMed Group stock opened at $23.84 on Tuesday. The stock has a market capitalization of $6.71 billion and a P/E ratio of -35.06. The firm has a 50-day simple moving average of $18.03. MiniMed Group has a 52 week low of $10.65 and a 52 week high of $24.43.

MiniMed Group (NASDAQ:MMED) last released its earnings results on Wednesday, June 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.46). The company had revenue of $837.00 million during the quarter. The business’s revenue was up 15.6% on a year-over-year basis. Analysts forecast that MiniMed Group will post 0.67 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. California State Teachers Retirement System purchased a new position in shares of MiniMed Group in the second quarter valued at $89,000. Readystate Asset Management LP purchased a new stake in MiniMed Group during the second quarter valued at $4,400,000. Washington Growth Strategies LLC purchased a new stake in MiniMed Group during the second quarter valued at $397,000. Punch & Associates Investment Management Inc. purchased a new stake in shares of MiniMed Group during the 2nd quarter valued at about $292,000. Finally, Bank of America Corp DE grew its position in MiniMed Group by 377.0% in the second quarter. Bank of America Corp DE now owns 238,819 shares of the company’s stock worth $3,570,000 after acquiring an additional 188,756 shares in the last quarter.

Key Stories Impacting MiniMed Group

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: Better fiscal Q1 performance: MiniMed reported higher-than-expected first-quarter sales, while fiscal Q1 EPS was reported at $0. The results helped drive the shares higher and prompted analysts to raise their forecasts. Analysts boost forecasts following Q1 sales results MiniMed shares rise after higher fiscal Q1 results
• Positive Sentiment: Broad analyst support: UBS raised its target from $25 to $28 and retained a “buy” rating; Bank of America lifted its target from $24 to $28; Mizuho increased its target from $21 to $26; Wells Fargo raised its target from $22 to $26; and Citigroup moved from $23 to $26, maintaining or initiating bullish ratings. Morgan Stanley also raised its target from $19 to $21 and assigned an “overweight” rating. The revisions signal improved expectations after the quarterly sales update, although Morgan Stanley’s target remains below the current trading level. Analyst expectations for MiniMed shares
• Positive Sentiment: Product and regulatory momentum: Coverage highlights a strong start to fiscal 2027, continued product development, and regulatory progress. A fresh product cycle and a greater contribution from recurring revenue could improve growth visibility and support investor confidence. MiniMed starts fiscal 2027 strongly Recurring revenues and fresh product cycle
• Neutral Sentiment: Valuation and execution remain considerations: The stock is trading close to its 52-week high after a substantial advance, leaving less room for disappointment. Investors will likely focus on whether product launches, regulatory milestones, and recurring revenue growth can justify the higher expectations.

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.